Qiagen N.V. (NYSE:QGEN) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Qiagen N.V. has received a consensus recommendation of "Hold" from twelve analysts, with nine ratings as hold and three as buy.
• The average 1-year target price from analysts for Qiagen is $49.40, while the stock opened at $46.93.
• In its latest quarter, Qiagen reported earnings of $0.60 per share, aligning with analyst expectations, and experienced a revenue increase of 7.7% year-over-year.

Qiagen N.V. (NYSE:QGEN - Get Free Report) has earned a consensus recommendation of "Hold" from the twelve ratings firms that are presently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $49.4008.

A number of equities analysts recently weighed in on the stock. Wall Street Zen cut shares of Qiagen from a "buy" rating to a "hold" rating in a research report on Saturday. Cowen reaffirmed a "hold" rating on shares of Qiagen in a research report on Thursday, August 7th. UBS Group increased their price objective on shares of Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Bank of America increased their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Finally, Barclays set a $53.00 price objective on shares of Qiagen and gave the stock an "overweight" rating in a research report on Thursday, October 2nd.

Qiagen Stock Performance

Qiagen stock opened at $46.93 on Friday. The firm has a 50 day simple moving average of $47.11 and a 200-day simple moving average of $45.50. Qiagen has a 1-year low of $37.63 and a 1-year high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The stock has a market cap of $10.43 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.46 and a beta of 0.66.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts expect that Qiagen will post 2.26 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Hedge funds have recently added to or reduced their stakes in the business. SVB Wealth LLC acquired a new stake in Qiagen during the 1st quarter worth approximately $31,000. MAI Capital Management raised its stake in Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company's stock worth $47,000 after acquiring an additional 889 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock worth $51,000 after acquiring an additional 849 shares in the last quarter. Allworth Financial LP increased its stake in Qiagen by 260.1% in the second quarter. Allworth Financial LP now owns 1,102 shares of the company's stock valued at $53,000 after purchasing an additional 796 shares during the period. Finally, Cullen Frost Bankers Inc. increased its stake in Qiagen by 13,144.4% in the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company's stock valued at $57,000 after purchasing an additional 1,183 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.